Pitfalls with Oral Drug Administration in IPF

In the first 3 parts of our blog series on targeted delivery in  idiopathic pulmonary fibrosis (IPF), we focused on the potential of inhaled delivery and other targeting strategies to deliver efficacy uplifts for agents as an add-on to the standard of care, while minimising the likelihood of additive side effects. In this fourth installment, we highlight […]

First-in-Human Clinical Trials

The Challenge: TherapeutAix was contacted by an innovative biotech company that was undertaking final preparations for First-in-Human clinical trials. It was known that their biologic has a complex metabolic pathway in vivo. One of the bioanalytical methods needed a major overhaul to be on the same technical level as the rest of the analytical toolbox. […]

Asset for Fibrotic Disease

The Challenge: TherapeutAix was approached by a US-based biotech company to review an asset that they were considering repositioning for fibrotic disease. The company asked for specific help in reviewing existing data, defining the steps then required to take the asset to IND-enabling studies and into the clinic.  The Action: The task was to review the […]

We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.

We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.

We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.

Marketing Permissions
Please select all the ways you would like to hear from TherapeutAix:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.